Skip to content

Hemastatx

Active
Private limited companyfounded 20251 yr activeRue Clément Ader 10, 6041 Charleroi, BelgiumKBO/BCE: BE 1019.406.058
Summary

Hemastatx has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€280,077) and a net result of -€280,078. Its solvency ranks better than 5% of 526 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.3% (low).

Checked score

Score 2025
Axes
Profitability0
Solvency0
Growth-
Track record67
Bankruptcy probability, 12 months
1.3% Low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.41; short-term debt: 239.5% and cash: 90.1% of total assets), and equity is negative.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
-139.5%
Return on assets
-139.5%
Age of the figures
9 mo
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 1 year 0 10 y
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-07-2026, 1 day ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2025
1 d early
← before the deadline after the deadline →
Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 30 January 2025, Hemastatx was incorporated as a Private limited company.1 The company has filed annual accounts once, for fiscal year 2025.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, micro schema

Equity
-€280,077
Total assets
€200,755
Net result
-€280,078
Working capital
-€284,089

Turnover and EBIT margin not published: the micro schema does not require them.

Balance-sheet composition
Assets €200,755
Fixed assets €4,013
Current assets €196,743
Key figures and ratios
2025 value
EBITDA
-€113,093
Cash flow
-€107,323
Solvency
-139.5%
Current ratio
0.41
Debt to equity
-1.72
ROA
-139.5%
Interest coverage
-3232.15
Debt
€480,832
Debt ≤ 1 year
€480,832
Income taxes
-€5,801
Staff costs
€77,003

Peer companies

Historical observation

Of the 1,322 companies that looked in July 2024 the way this one looks now, 4.2% went bankrupt within 24 months and 90% are still going.

  • Micro
  • under 2 years old
  • negative equity
  • a loss of 10% of the balance sheet or more
4.2% went bankrupt
5.5% stopped otherwise
90% still going

For this company itself Checked computes a bankruptcy probability of 1.3% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,338 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.9%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 1,322 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 · 37 lines
Balance sheet Code2025
Assets
Total assets20/58€200,755
Fixed assets21/28€4,013
Intangible fixed assets21€3,212
Tangible fixed assets22/27€800
Furniture and vehicles24€800
Current assets29/58€196,743
Amounts receivable after more than one year29€5,801
Other amounts receivable291€5,801
Amounts receivable within one year40/41€9,998
Trade receivables40€4,523
Other amounts receivable41€5,475
Cash at bank and in hand54/58€180,810
Deferred charges and accrued income490/1€134
Equity and liabilities
Total equity and liabilities10/49€200,755
Equity10/15-€280,077
Contributions10/11€1
Profit (loss) carried forward14-€280,078
Amounts payable17/49€480,832
Amounts payable within one year42/48€480,832
Trade debts44€8,968
Suppliers440/4€8,968
Taxes, remuneration and social security45€11,863
Remuneration and social security454/9€11,863
Other amounts payable47/48€460,000
Income statement Code2025
Remuneration, social security and pensions62€77,003
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€172,755
Gross operating margin9900-€36,090
Operating profit (loss)9901-€285,848
Financial income75/76B€5
Recurring financial income75€5
Financial charges65/66B€35
Recurring financial charges65€35
Profit (loss) for the period before taxes9903-€285,878
Income taxes67/77-€5,801
Profit (loss) for the period9904-€280,078
Profit (loss) for the period to be appropriated9905-€280,078
Appropriation of the result
Profit (loss) to be appropriated9906-€280,078

The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2025
Remuneration, social security and pensions62€77,003
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€172,755
Gross operating margin9900-€36,090
Operating profit (loss)9901-€285,848
Financial income75/76B€5
Recurring financial income75€5
Financial charges65/66B€35
Recurring financial charges65€35
Profit (loss) for the period before taxes9903-€285,878
Income taxes67/77-€5,801
Profit (loss) for the period9904-€280,078
Profit (loss) for the period to be appropriated9905-€280,078
Line2025
Assets
Total assets20/58€200,755
Fixed assets21/28€4,013
Intangible fixed assets21€3,212
Tangible fixed assets22/27€800
Furniture and vehicles24€800
Current assets29/58€196,743
Amounts receivable after more than one year29€5,801
Other amounts receivable291€5,801
Amounts receivable within one year40/41€9,998
Trade receivables40€4,523
Other amounts receivable41€5,475
Cash at bank and in hand54/58€180,810
Deferred charges and accrued income490/1€134
Equity and liabilities
Total equity and liabilities10/49€200,755
Equity10/15-€280,077
Contributions10/11€1
Profit (loss) carried forward14-€280,078
Amounts payable17/49€480,832
Amounts payable within one year42/48€480,832
Trade debts44€8,968
Suppliers440/4€8,968
Taxes, remuneration and social security45€11,863
Remuneration and social security454/9€11,863
Other amounts payable47/48€460,000
Line2025
Profit (loss) for the period9904-€280,078
+ Depreciation and write-downs630€172,755
Operating cash flow (approximation)-€107,323

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2026
30-07
NBB filing Annual accounts filed
fiscal year 2025 · micro schema
NBB filing
0 of 1 act read
About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Charleroi · 1 establishment unit since 2025
seat establishment approximate The establishment unit on the map
Ground area
7,830 m²
Parcel 52028B0295/02C000, Wallonia. Linked by address, not a title deed.
1 establishment unit
Hemastatx
Rue Clément Ader 10, 6041 CharleroiManufacture of basic pharmaceutical products and pharmaceutical preparations
since 20252.369.570.933
1 parcel
Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
52028B0295/02C000 Wallonia 7,830 m² - -
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Similar companies · same sector and region

This company's figures show no positive equity and no headcount, so a size comparison is not possible. These companies share only the sector and the region. Of 762 companies in sector 72101 we hold annual accounts for 484. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded30-01-2025
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
72109Other research and development on natural sciences
77400Rental and leasing activities
E-invoicing
Reachable via Peppol
Peppol ID 0208:1019406058
Registered 03-02-2025

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 29 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.